Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: Impact on in vitro-in vivo extrapolation of drug clearance

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 982-989

  Wattanachai, Nitsupa ^a   Tassaneeyakul, Wichittra ^a,b   Rowland, Andrew ^c   Elliot, David J ^c   Bowalgaha, Kushari ^c   Knights, Kathleen M ^c   Miners, John O ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; CYTOCHROME P450 1A2; LIDOCAINE; LINOLEIC ACID; OLEIC ACID; PHENACETIN; RECOMBINANT ENZYME;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DEETHYLATION; DRUG BINDING; DRUG CLEARANCE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANIMALS; CATALYSIS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; ESCHERICHIA COLI; FATTY ACIDS, UNSATURATED; HUMANS; KINETICS; LIDOCAINE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHENACETIN; PREDICTIVE VALUE OF TESTS; SERUM ALBUMIN, BOVINE; SUBSTRATE SPECIFICITY;

BOVINAE; ESCHERICHIA COLI;

EID: 84859886181     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044057     Document Type: Article

References (50)

1. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503. (Pubitemid 35356875)
2. Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, and Birkett DJ (2004) Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica 34:49-60. (Pubitemid 38187062)
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaprocen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433. (Pubitemid 41428474)
4. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, and Schenkman JB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1B1. Drug Metab Dispos 32:840-847. (Pubitemid 38955614)
5. De Martin S, Orlando R, Bertoli M, Pegoraro P, and Palatini P (2006) Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther 80:597-606. (Pubitemid 44908268)
6. Donato MT, Hallifax D, Picazo L, Castell JV, Houston JB, Gomez-Lechón MJ, and Lahoz A (2010) Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. Drug Metab Dispos 38:1449-1455.
7. Gillam EM and Reilly PE (1988) Phenacetin O-deethylation by human liver microsomes: kinetics and propranolol inhibition. Xenobiotica 18:95-104. (Pubitemid 18051824)
8. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
9. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
10. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486. (Pubitemid 38519653)
11. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
12. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)
13. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
14. Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, and Chiba K (1999) Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860-865. (Pubitemid 29347584)
15. max values of UGT1A9. Drug Metab Dispos 39:2117-2129.
16. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461. (Pubitemid 30229449)
17. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
18. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
19. Nation RL, Triggs EJ, and Selig M (1977) Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol 4:439-448. (Pubitemid 8162357)
20. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
21. Olkkola KT, Isohanni MH, Hamunen K, and Neuvonen PJ (2005) The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth Analg 100:1352-1356. (Pubitemid 40577383)
22. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, and Palatini P (2004) Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 75:80-88. (Pubitemid 38130120)
23. Orlando R, Piccoli P, De Martin S, Padrini R, and Palatini P (2003) Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 55:86-93. (Pubitemid 36110843)
24. Polasek TM, Elliot DJ, and Miners JO (2006a) Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitro. Curr Protoc Toxicol 27:4.19.11-14.19.11.
25. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, and Miners JO (2006b) An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570-584.
26. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178. (Pubitemid 38299716)
27. Raaflaub J and Dubach UC (1975) On the pharmacokinetics of phenacetin in man. Eur J Clin Pharmacol 8:261-265.
28. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, and Miners JO (2010) In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther 334:609-618.
29. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311. (Pubitemid 41196973)
30. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008a) The "albumin effect"and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877. (Pubitemid 351574884)
31. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062. (Pubitemid 43763765)
32. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
33. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008b) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
34. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2009) Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos 37:1395-1403.
35. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892-896. (Pubitemid 34815418)
36. Tang C, Lin Y, Rodrigues AD, and Lin JH (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648-654. (Pubitemid 34579097)
37. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, and Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776. (Pubitemid 24172844)
38. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407. (Pubitemid 23320988)
39. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, and Miners JO (1992) Caffeine as a probe for human cytochromes P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
40. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199. (Pubitemid 37518547)
41. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
42. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1998) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502-1507.
43. Veronese ME, McLean S, D'Souza CA, and Davies NW (1985) Formation of reactive metabolites of phenacetin in humans and rats. Xenobiotica 15:929-940. (Pubitemid 16219464)
44. Vesell ES, Passananti GT, Glenwright PA, and Dvorchik BH (1975) Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther 18:259-272.
45. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122. (Pubitemid 28006177)
46. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, and Kivistö KT (2000) Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959-965. (Pubitemid 30612616)
47. Wattanachai N, Polasek TM, Heath TM, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, and Miners JO (2011) In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815-824.
48. Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, and Wanwimolruk S (1984) Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther 35: 695-701. (Pubitemid 14108758)
49. Yamazaki H and Shimada T (1999) Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29:231-241. (Pubitemid 29140093)
50. Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, and Yeh TK (2006) The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 79:2432-2440. (Pubitemid 44781104)